SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 184.780.0%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dwc who wrote (16351)3/3/1998 4:05:00 PM
From: Henry Niman  Read Replies (3) of 32384
 
Actually, The report wasn't all that unexpected. Most of the events were anticipated. However, a forth NDA filing this year should really catch the street's attention. If LGND could pull off 2 Phase IIs substituting for one Phase III, it would demonstrate that the FDA is serious about getting "slam dunks" onto pharmacy shelves, especially when the disease is life threatening. It would also give the FDA a chance to show that the "fast track" works for the little guys also.
Since LGND's profile will be relatively high (three major conferences in 4 months including several presentations by the AIDS Consortium as well as LGND), the FDA may decide to tell LGND to "go for it".

Not too many Biotechs (or Pharmas) in a position to file 4 NDAs in one year. With Biotechs continuing to disappoint, LGND has to start standing out.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext